Indications for TRIVISC:
Treatment of pain in osteoarthritis of the knee in patients who have failed nonpharmacologic therapy and simple analgesics (eg, acetaminophen).
Remove joint effusion, if present, before inj. Give as a single intra-articular inj. >21yrs: 2.5mL in one knee only at weekly intervals for 3 weeks. If bilateral, use separate syringes for each knee. May use SC lidocaine or similar local anesthetic prior to inj.
≤21yrs: not established.
Knee joint infections. Skin diseases in area of the inj site.
Effectiveness of a single treatment cycle of <3 injections or repeated treatment cycles: not established. Advise patients to avoid strenuous or prolonged weight-bearing activities for approx. 48hrs following inj. Pregnancy, nursing mothers: not established.
Avoid use of disinfectants containing quaternary ammonium salts; hyaluronan can precipitate in their presence. Concomitant other intra-articular inj: not established.
Inj site pain, allergic reaction, arthralgia, bleeding at the inj site, bleeding, heaviness; transient knee inflammation.
Generic Drug Availability:
Single-use prefilled syringe—1